Hope in ALS: Spinogenix unveils promising results for its regenerative therapy SPG302

Biotechnology company Spinogenix has announced encouraging top-line results from its Phase 2a clinical trial of SPG302, an innovative treatment designed to restore lost neural connections in patients with Amyotrophic Lateral Sclerosis (ALS).

The study, which enrolled 23 participants, showed signs of slowing disease progression, with improvements in motor and cognitive function compared with historical controls. SPG302 works by regenerating synapses—the tiny junctions between neurons responsible for movement, thought, and memory—offering a therapeutic strategy that goes beyond merely halting the disease: it aims to repair neurological damage.

“We are seeing early evidence that we can restore lost neuronal connections. This could be a paradigm shift for diseases like ALS,” said Dr. Stella Sarraf, CEO of Spinogenix.

The treatment was well tolerated, with no serious adverse events reported, and could mark the beginning of a new era of regenerative neuroscience therapies, combining cellular biology and artificial intelligence to optimize clinical outcomes.